Roche joins Californian Nurix oncology programme
Keystone-SDA
Swiss pharmaceutical giant Roche is shelling out $700 million to join the research of Californian counterpart Nurix Therapeutics on the drug bexobrutideg.
+ Get the most important news from Switzerland in your inbox
The product against chronic lymphocytic leukaemia (CLL) is expected to enter the final phase of development this summer, the two companies specify in separate releases.
The investigational Bruton’s tyrosine kinase (TKB) degrader is being developed not only against B-cell lymphomas, but also for potential applications in neurology and immunology.
The total value of the contract could reach up to $2.3 billion, subject to the achievement of pre-defined targets. In case of success, profit or loss in the US will be shared equally between Roche and Nurix. Outside the US, Nurix will receive a commission of between 10% and 20% of Roche’s revenues.
In the future, Roche will bear 60% of the development costs of bexobrutideg, it is further noted.
Roche points out that the combined CLL and non-Hodgkin’s lymphoma market is expected to reach $41 billion by 2031, of which $19 billion is attributable to TKB inhibitors alone.
More
More
FDA approves Roche leukaemia treatment
Translated from Italian by AI/mga
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
